Skip to main content
. 2017 Jun 8;12(6):e0179248. doi: 10.1371/journal.pone.0179248

Fig 4. Zoledronate affected osteoclast formation and secretion of PDGF-BB.

Fig 4

(a-c) Zoledronate affected viability of OPCs, MSCs and EPCs for 24, 48, 72 h. After a 48 h incubation, Zoledronate significantly inhibited the activity of OPCs at 0.1 μM (a) and showed obvious toxicity to EPCs and MSCs at 10 μM (b,c). (d) TRAP staining and DAPI counterstaining were made to show that zoledronate affected osteoclast formation. (e) Infusion index showed that zoledronate began to inhibit osteoclast formation obviously at 0.5 μM. (f) PDGF-BB secretion by ELISA also significantly decreased when treated by zoledronate at 0.5 μM for 48 h.